KYMR241220P55000
- 0.00
- 0.000.00%
Kymera Therapeutics Newsroom
BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60
Kymera Therapeutics Initiated at Market Perform by BMO Capital
Kymera Therapeutics Analyst Ratings
BMO Capital Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $55
Cautious Optimism for Kymera Therapeutics: Hold Rating Amid Uncertainties in Innovative Protein Degradation Programs
Wells Fargo Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Raises Target Price to $57
Kymera Therapeutics (KYMR) Gets a Hold From Wells Fargo
Stephens Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $65
Kymera Therapeutics Price Target Announced at $65.00/Share by Stephens & Co.
Kymera Therapeutics Initiated at Overweight by Stephens & Co.
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
UBS Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $74
Kymera Therapeutics Is Maintained at Buy by UBS
Kymera Therapeutics Analyst Ratings
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56